Nom du produit:6-chloro-7H-purin-2-amine

IUPAC Name:6-chloro-7H-purin-2-amine

CAS:10310-21-1
Formule moléculaire:C5H4ClN5
Pureté:98%
Numéro de catalogue:CM105259
Poids moléculaire:169.57

Unité d'emballage Stock disponible Prix($) Quantité
CM105259-500g in stock ȁȁɅ
CM105259-1000g in stock ŴŴǧ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:10310-21-1
Formule moléculaire:C5H4ClN5
Point de fusion:-
Code SMILES:NC1=NC(Cl)=C2NC=NC2=N1
Densité:
Numéro de catalogue:CM105259
Poids moléculaire:169.57
Point d'ébullition:
N° Mdl:MFCD00075252
Stockage:Protect form light and store in a dry and close container at room temperature

Category Infos

Purines
Purines are heterocyclic aromatic compounds composed of linked pyrimidine and imidazole rings. In mammals, purines are most commonly expressed in DNA and RNA (including the purines adenine and guanine), as well as single-molecule nucleotides (adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, and to a lesser extent guanosine triphosphate (GTP) and cyclic guanosine monophosphate (cGMP). Purines are also key elements of the following energy metabolism molecules: reduced nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate (NADPH), and coenzyme Q. Purines can also act as direct neurotransmitters; for example, adenosine may interact with receptors to modulate cardiovascular and central nervous system (CNS) function.
purine wholesale
Find trusted purine wholesaler. Any requirements and problems can ask us at any time.
Nucleosides and Nucleotides
Nucleosides consist of a nucleotide and a five-carbon sugar, and a nucleotide consists of a nucleotide, a five-carbon sugar, and one or more phosphate groups.
nucleoside manufacturer
As a professional nucleoside manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

Column Infos

Ibezapolstat
Acurx announces successful FDA end-of-phase 2 meeting and phase 3 readiness for Ibezapolstat in the treatment of C. difficile infection. The successful meeting outcomes include reaching key elements of Phase 3 clinical trial program and a development plan of NDA filling. C. difficile infection (CDI) is a bacterial infection of the colon, and causes diarrhea and colitis.
Ibezapolstat is a novel antibacterial agent that acts specially on DNA pol IIIC enzyme through competitive inhibition of dGTP (guanosine analog). Ibezapolstat has been granted Fast Track Designation from the U.S. FDA.